Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$163.79 USD

163.79
5,849,887

+2.98 (1.85%)

Updated May 3, 2024 04:00 PM ET

After-Market: $163.01 -0.78 (-0.48%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

4 Best Marijuana Stocks to Play the Green Rush

by Zacks Equity Research

Not only is marijuana one of the fastest growing industries in the U.S., but it also received a major boost after the 2016 election. Find out which stocks you should play the green rush with.

    McKesson (MCK) Q3 Earnings: Stock Likely to Disappoint?

    by Zacks Equity Research

    McKesson Corporation (MCK), one of the largest healthcare services providers, is scheduled to report third-quarter fiscal 2017 results on Jan 25.

      Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

      by Zacks Equity Research

      Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

        Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?

        by Zacks Equity Research

        Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.

          Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?

          by Zacks Equity Research

          We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.

            Allergan's Uterine Fibroids Candidate Positive in Phase III

            by Zacks Equity Research

            Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding due to uterine fibroids.

              What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?

              by Zacks Equity Research

              Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.

                Coherus Offers Positive Phase III Data on Humira Biosimilar

                by Zacks Equity Research

                Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.

                  AbbVie's HCV Combo Favorable in Japanese Phase III Study

                  by Zacks Equity Research

                  AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.

                    Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)

                    by Zacks Equity Research

                    Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.

                      Pfizer's Humira Biosimilar Meets Primary Endpoint in Study

                      by Zacks Equity Research

                      Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.

                        AbbVie's Humira and Imbruvica Drive Performance in 2016

                        by Zacks Equity Research

                        AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

                          Roche (RHHBY) Hemophilia A Drug Positive in Phase III

                          by Zacks Equity Research

                          Roche (RHHBY) announced that the phase III study, HAVEN 1, met its primary endpoint.

                            The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, U.S. Bancorp, Baker Hughes and Southwest Airlines

                            by Zacks Equity Research

                            The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, U.S. Bancorp, Baker Hughes and Southwest Airlines

                              AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US

                              by Zacks Equity Research

                              AbbVie Inc. (ABBV) announced that it has submitted a New Drug Application (NDA) to the FDA for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                                Sheraz Mian headshot

                                Analyst Reports for Union Pacific, AbbVie & U.S. Bancorp

                                by Sheraz Mian

                                Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and U.S. Bancorp (USB).

                                  Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

                                  by Zacks Equity Research

                                  Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

                                    Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls

                                    by Zacks Equity Research

                                    Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.

                                      Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

                                      by Zacks Equity Research

                                      Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

                                        AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH

                                        by Zacks Equity Research

                                        AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.

                                          Amgen/Allergan File for EU Approval of Avastin Biosimilar

                                          by Zacks Equity Research

                                          Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

                                            AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.

                                            by Zacks Equity Research

                                            AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.

                                              Momenta/Shire's Humira Biosimilar Meets Study Objective

                                              by Zacks Equity Research

                                              Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.

                                                The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                                                by Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                                                  Sheraz Mian headshot

                                                  Top Research Reports for Cisco, Amgen & NextEra Energy

                                                  by Sheraz Mian

                                                  Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and NextEra Energy (NEE).